TNFRSF17 and hematopoietic and lymphoid cell neoplasm: The molecular design of the CAR, along with advancements in molecular techniques and the development of “omics”, has opened the possibility of discovering new therapeutic targets and thereby expanding the range of diseases treated with CAR-T cells beyond the use of anti-CD19 and anti-BCMA for hematologic cancer.